Diabetic retinopathy is caused by damage to the blood vessels at the back of the eye (retina) that can lead to blindness.
After 20 years of diabetes, nearly 99 percent of patients with Type 1 and 60 percent of those with Type 2 will have some form of Diabetic Retinopathy.
Most common course of treatment is monthly injections to the eye.
A novel patented PEDF (pigment epithelium-derived factor) derived peptide that has shown to have therapeutic effect in mouse and primate diabetic retinopathy models delivered via eye drops by reducing inflammation, cell death and vascular leakage.
Preliminary data indicates that these proprietary PEDF derived peptides could be a platform therapeutic for other ophthalmic degenerative diseases.